Last reviewed · How we verify
Adapalene Gel
Adapalene Gel is a Retinoid Small molecule drug developed by Bausch Health Americas, Inc.. It is currently FDA-approved for Acne vulgaris. Also known as: Differin Gel .3%, Differin.
Adapalene is a third-generation retinoid that binds to retinoic acid receptors to normalize skin cell differentiation and reduce inflammation.
Adapalene gel is a small molecule that acts as a retinoic acid receptor agonist. It is used to treat acne and acne vulgaris, as indicated by clinical trials.
At a glance
| Generic name | Adapalene Gel |
|---|---|
| Also known as | Differin Gel .3%, Differin |
| Sponsor | Bausch Health Americas, Inc. |
| Drug class | Retinoid |
| Target | Retinoic acid receptor gamma (RAR-γ) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Adapalene selectively binds to retinoic acid receptor gamma (RAR-γ) and other retinoid receptors, promoting keratinocyte differentiation and reducing sebum production. It decreases comedone formation and has anti-inflammatory properties, making it effective for treating acne by normalizing follicular epithelial desquamation and reducing bacterial colonization.
Approved indications
- Acne vulgaris
Common side effects
- Erythema
- Scaling
- Dryness
- Pruritus
- Photosensitivity
Key clinical trials
- Topical 5% Spironolactone Gel Versus 0.1% Adapalene Gel for Acne Vulgaris: A Randomized Split-Face Study (PHASE2)
- Evaluation of Topical Dutasteride as a Potential New Therapy for Facial Acne Vulgaris Versus the Triple Combination Therapy (Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel) (NA)
- Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris
- Auricular Acupressure Combined With Adapalene for the Treatment of Acne Vulgaris (NA)
- Experience With Topical Acne Treatment (EARLY_PHASE1)
- Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel (PHASE2)
- A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Adapalene 0.3% for the Treatment of Acne (PHASE4)
- Efficacy and Safety of Adapalene Gel and Hyaluronic Acid Versus Adapalene Gel Alone in Mild to Moderate Acne Vulgaris (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adapalene Gel CI brief — competitive landscape report
- Adapalene Gel updates RSS · CI watch RSS
- Bausch Health Americas, Inc. portfolio CI
Frequently asked questions about Adapalene Gel
What is Adapalene Gel?
How does Adapalene Gel work?
What is Adapalene Gel used for?
Who makes Adapalene Gel?
Is Adapalene Gel also known as anything else?
What drug class is Adapalene Gel in?
What development phase is Adapalene Gel in?
What are the side effects of Adapalene Gel?
What does Adapalene Gel target?
Related
- Drug class: All Retinoid drugs
- Target: All drugs targeting Retinoic acid receptor gamma (RAR-γ)
- Manufacturer: Bausch Health Americas, Inc. — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Acne vulgaris
- Also known as: Differin Gel .3%, Differin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing